NEW YORK--(BUSINESS WIRE)--Oct. 17, 2005--IRX Therapeutics, a privately-held company dedicated to the development and commercialization of novel drugs for the treatment of cancer and viral diseases, today announced the first patients in its IRX-2 Phase II head and neck cancer clinical trial have been enrolled and treated.
